GlassScriptPhysician profile
Robert M Hamilton
NPI 1619526621
$4,018.71
in general payments reported to CMS, 2019-2025
33 companies · $2,348 in 2025
The $2,348 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $267 · 2024: $1,405 · 2025: $2,348.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,732 · Education: $247 · Travel and Lodging: $40.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,731.72 |
| Education | $246.99 |
| Travel and Lodging | $40.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $732.23 | 2024-2025 | Inspire |
| Jazz Pharmaceuticals INC. | $455.84 | 2023-2025 | |
| Harmony Biosciences LLC | $443.70 | 2023-2025 | Wakix |
| Axsome Therapeutics, INC. | $384.84 | 2023-2025 | Sunosi |
| Avadel Cns Pharmaceuticals, LLC | $300.92 | 2023-2025 | Lumryz |
| Glaxosmithkline, LLC. | $206.30 | 2023-2025 | Shingrix, Arexvy |
| Lilly USA, LLC | $182.37 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $181.45 | 2024-2025 | |
| Idorsia Pharmaceuticals US INC | $152.51 | 2024 | Quviviq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $137.68 | 2023-2025 | Jardiance, Tradjenta, Synjardy |
| Abbvie INC. | $116.73 | 2023-2025 | |
| Novo Nordisk INC | $82.66 | 2023-2025 | Ozempic, Rybelsus |
| Exeltis, USA INC. | $67.34 | 2025 | Twirla, Slynd |
| Amgen INC. | $55.08 | 2024-2025 | Repatha, Otezla, Otezla |
| Phathom Pharmaceuticals, INC. | $52.34 | 2025 | Voquezna |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $51.62 | 2023-2024 | Ingrezza, Ongentys |
| Averitas Pharma INC. | $44.70 | 2024-2025 | Qutenza |
| Astrazeneca Pharmaceuticals LP | $44.31 | 2024-2025 | Breztri, Airsupra |
| Novartis Pharmaceuticals Corporation | $38.57 | 2024-2025 | |
| Pfizer INC. | $36.30 | 2024 | |
| 3b Medical, INC. | $32.47 | 2025 | Luna |
| Daiichi Sankyo INC. | $29.32 | 2025 | Injectafer |
| Madrigal Pharmaceuticals | $25.94 | 2025 | Rezdiffra |
| Philips North America LLC | $20.49 | 2024 | (Di7) Home Pi Undivided |
| Actelion Pharmaceuticals US, INC. | $19.12 | 2024 | Opsumit |
| Sanofi-Aventis U.S. LLC | $18.31 | 2025 | |
| Merck Sharp & Dohme LLC | $17.69 | 2025 | Capvaxive |
| Azurity Pharmaceuticals, INC. | $17.08 | 2025 | Horizant |
| Dexcom, INC. | $16.74 | 2024 | Dexcom G6 Transmitter |
| Baxter Healthcare | $14.80 | 2023 | Hillrom - Life 2000 Ventilation System |
| Sanofi Pasteur INC. | $13.65 | 2025 | |
| Grifols USA, LLC | $13.56 | 2024 | Prolastin-C Liquid |
| Sumitomo Pharma America, INC. | $12.05 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Hamilton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.